[Variability of ceftazidime pharmacokinetics in children with suppurative-septic diseases]

Area of Science:

• Neonatal pharmacokinetics
• Infectious disease pharmacotherapy
• Antibiotic drug monitoring

Background:

• Purulent septic infections in neonates and infants present complex therapeutic challenges.
• Standard antibiotic dosing may not be effective due to pharmacokinetic variability in critically ill neonates and infants.
• Ceftazidime is a critical antibiotic for treating serious bacterial infections in this population.

Purpose of the Study:

• To investigate the pharmacokinetic variability of ceftazidime in newborns and infants with purulent septic infections.
• To determine the impact of critical care interventions on ceftazidime pharmacokinetics.
• To establish recommendations for optimizing ceftazidime therapy in this vulnerable patient group.

Main Methods:

• Pharmacokinetic analysis of ceftazidime plasma concentrations (Cmax and T1/2).
• Study conducted on 3 newborns and 2 infants with purulent septic infections.
• Patients received complex intensive care, including artificial pulmonary ventilation and infusions.

Main Results:

• Significant inter-individual variability in ceftazidime pharmacokinetics (Cmax and T1/2) was observed.
• Variability suggests altered drug distribution and excretion patterns in critically ill neonates and infants.
• These pharmacokinetic changes can impact treatment efficacy and safety.

Conclusions:

• Monitoring ceftazidime plasma concentrations is recommended for neonates and infants with severe infections.
• Therapeutic drug monitoring is essential to prevent antibiotic failure and ensure optimal outcomes.
• High-performance liquid chromatography (HPLC) is a suitable method for monitoring ceftazidime levels.